EUVIMEDEUVIMED entdecken
Crossref

Pharmacological Mechanism of Mume Fructus in the Treatment of Triple-Negative Breast Cancer Based on Network Pharmacology

Lei Yin, Yan Qi, Yuting Jiang

Applied Biochemistry and Biotechnology · 2024

DOI: 10.1007/s12010-024-04948-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Applied Biochemistry and Biotechnology, 2024. Verfasst von Lei Yin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, The Second Affiliated Hospital of Shandong First Medical University, Taian, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms. Die Arbeit nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Our study aims to find the relevant mechanism of Mume Fructus in the treatment of triple-negative breast cancer (TNBC) by network pharmacology analysis and experimental validation. The effective compounds of Mume Fructus and TNBC-related target genes were imported into Cytoscape to construct a Mume Fructus-effective compounds-disease target network. The common targets of Mume Fructus and TNBC were determined by drawing Venn diagrams. Then, the intersection targets were transferred to the STRING database to construct a protein-protein interaction (PPI) network. To investigate the mechanism of Mume Fructus in treatment of TNBC, breast cancer cell (MDA-MB-231) was treated with Mume Fructus and/or transfected with small interference RNA-PKM2(siPKM2). CCK-8 assay, cell clonal formation assay, transwell, flow cytometry, qRT-PCR, and western blotting were performed. Eight effective compounds and 145 target genes were obtained, and the Mume Fructus- effective compounds-disease target network was constructed. Then through the analysis of the PPI network, we obtained 10 hub genes including JUN, MAPK1, RELA, AKT1, FOS, ESR1, IL6, MAPK8, RXRA, and MYC. KEGG enrichment analysis showed that JUN, MAPK1, RELA, FOS, ESR1, IL6, MAPK8, and RXRA were enriched in the Th17 cell differentiation signaling pathway. Loss of PKM2 and Mume Fructus both inhibited the malignant phenotype of MDA-MB-231 cells. And siPKM2 further aggravated the Mume Fructus inhibition of malignancy of breast cancer cells. Network pharmacology analysis suggests that Mume Fructus has multiple therapeutic targets for TNBC and may play a therapeutic role by modulating the immune microenvironment of breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsHumansCell Line, TumorFemaleNetwork PharmacologyProtein Interaction MapsDrugs, Chinese HerbalGene Expression Regulation, NeoplasticCell Proliferation

Stichwörter der Autor:innen

ApoptosisGeneMume FructusNetwork pharmacologyProliferationTriple-negative breast cancer

Substanzen

Drugs, Chinese Herbal

Autor:innen und Institutionen

  • Department of Breast Surgery, The Second Affiliated Hospital of Shandong First Medical University, Taian, China.
  • Operating Theater of the Second Affiliated Hospital of Shandong First Medical University, Taian, China.
  • Department of Traditional Chinese Medicine, The Second Affiliated Hospital of Shandong First Medical University, Taian, China. 13615482469@163.com.

Zitieren

APA

Yin, L., Qi, Y., & Jiang, Y. (2024). Pharmacological Mechanism of Mume Fructus in the Treatment of Triple-Negative Breast Cancer Based on Network Pharmacology. Applied Biochemistry and Biotechnology. https://doi.org/10.1007/s12010-024-04948-w

Vancouver

Yin L, Qi Y, Jiang Y. Pharmacological Mechanism of Mume Fructus in the Treatment of Triple-Negative Breast Cancer Based on Network Pharmacology. Applied Biochemistry and Biotechnology. 2024. doi:10.1007/s12010-024-04948-w

BibTeX
@article{Yin2024,
  author = {Yin, Lei and Qi, Yan and Jiang, Yuting},
  title = {Pharmacological Mechanism of Mume Fructus in the Treatment of Triple-Negative Breast Cancer Based on Network Pharmacology},
  journal = {Applied Biochemistry and Biotechnology},
  year = {2024},
  doi = {10.1007/s12010-024-04948-w}
}
Kostenlos starten →